Overview

Safety of Bryostatin in Patients With MS

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).

Phase:

Phase 1

Details

Lead Sponsor:

Robert Fox

Collaborator:

Synaptogenix, Inc.

Treatments:

Bryostatin 1